Biosig Technologies (NASDAQ:STEX) Director Buys $71,910.00 in Stock

Biosig Technologies, Inc. (NASDAQ:STEX) Director Morgan Lee Lekstrom acquired 23,500 shares of the firm’s stock in a transaction dated Tuesday, February 3rd. The stock was bought at an average cost of $3.06 per share, for a total transaction of $71,910.00. Following the purchase, the director directly owned 102,500 shares of the company’s stock, valued at approximately $313,650. This trade represents a 29.75% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Morgan Lee Lekstrom also recently made the following trade(s):

• On Thursday, January 29th, Morgan Lee Lekstrom bought 2,500 shares of Biosig Technologies stock. The stock was purchased at an average cost of $3.70 per share, with a total value of $9,250.00.
• On Monday, January 26th, Morgan Lee Lekstrom bought 23,000 shares of Biosig Technologies stock. The shares were purchased at an average price of $3.30 per share, for a total transaction of $75,900.00.
• On Tuesday, January 27th, Morgan Lee Lekstrom bought 5,500 shares of Biosig Technologies stock. The shares were purchased at an average price of $3.12 per share, for a total transaction of $17,160.00.
• On Friday, January 23rd, Morgan Lee Lekstrom bought 41,000 shares of Biosig Technologies stock. The stock was purchased at an average cost of $3.13 per share, with a total value of $128,330.00.

Biosig Technologies Stock Performance

STEX stock traded up $0.01 during trading on Tuesday, reaching $3.34. The company’s stock had a trading volume of 1,828,225 shares, compared to its average volume of 1,702,008. The firm has a market capitalization of $533.06 million, a PE ratio of -2.47 and a beta of 1.50. Biosig Technologies, Inc. has a 1 year low of $0.40 and a 1 year high of $14.11.

Analysts Set New Price Targets

Separately, Weiss Ratings started coverage on Biosig Technologies in a research note on Friday, January 23rd. They issued a “sell (d-)” rating for the company. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company currently has a consensus rating of “Sell”.

Biosig Technologies Company Profile

Biosig Technologies (NASDAQ:STEX) is a medical technology company focused on developing advanced signal acquisition and processing solutions for cardiac electrophysiology. The company’s work centers on improving the clarity and interpretability of intracardiac signals captured during electrophysiology procedures, with the goal of helping clinicians identify arrhythmogenic substrates and make more informed procedural decisions.

Its primary offering is a signal-processing platform that combines proprietary hardware and software to amplify, filter and display intracardiac electrical activity with reduced noise and distortion.